Iovance Biotherapeutics Free Cash Flow Yield Over Time
| IOVA Stock | USD 9.40 0.28 3.07% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Iovance Biotherapeutics Performance and Iovance Biotherapeutics Correlation. Iovance |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.29) | Return On Equity (0.57) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Yield Analysis
Compare Iovance Biotherapeutics and related stocks such as PTC Therapeutics, Krystal Biotech, and Sarepta Therapeutics Free Cash Flow Yield Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCT | (0.0895) | (0.0895) | (0.2057) | (0.2195) | (0.0379) | (0.1166) | (0.2836) | (0.0202) | (0.027) | (0.051) | (0.0621) | (0.12) | (0.186) | (0.1353) | (0.14) |
| KRYS | (0.0291) | (0.0291) | (0.0291) | (0.0291) | (0.0291) | (0.0291) | (0.0291) | (0.0727) | (0.0502) | (0.0285) | (0.0363) | (0.0749) | (0.076) | (0.0299) | (0.0314) |
| SRPT | (0.0438) | (0.2673) | (0.0507) | (0.0994) | (0.2682) | (0.0946) | (0.1892) | (0.0774) | (0.0627) | (0.0547) | 0.0019 | (0.0658) | (0.0314) | (0.066) | (0.0693) |
| MDGL | (0.1227) | (0.2177) | (0.102) | (0.2102) | (0.303) | (34.1315) | (0.2271) | (0.02) | (0.0153) | (0.0298) | (0.0919) | (0.1314) | (0.0452) | (0.0753) | (0.0791) |
| CVAC | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0106) | 0.0542 | (0.1534) | (0.3563) | (0.3847) | (0.37) |
| APLS | (0.0136) | (0.0136) | (0.0136) | (0.0136) | (0.0393) | (0.0743) | (0.1024) | (0.1548) | (0.1829) | (0.1117) | (0.0386) | (0.1414) | (0.0939) | (0.0838) | (0.088) |
| OCEA | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (3.0E-4) | (0.008) | (0.002) | (0.0023) | (0.0024) |
| HEPA | 0.0 | 0.0 | 0.0 | (0.097) | (0.0883) | (0.5885) | (0.5676) | (0.2945) | (4.3109) | (0.6955) | (0.7669) | (0.3913) | (1.5295) | (3.1793) | (3.02) |
Iovance Biotherapeutics and related stocks such as PTC Therapeutics, Krystal Biotech, and Sarepta Therapeutics Free Cash Flow Yield description
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.My Equities
My Current Equities and Potential Positions
| Iovance Biotherapeutics | IOVA |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 9.4
Check out Iovance Biotherapeutics Performance and Iovance Biotherapeutics Correlation. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Iovance Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.